SCHEMBL23925546

SCHEMBL23925546

Cc1ccc2[nH]cc(CCNC(=O)Nc3ccc(Cl)c(Cl)c3)c2c1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GOT1 P17174 2/20 0.75
MAPT P10636 5/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
POLB P06746 1/20 0.73
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
MTNR1A P48039 2/20 0.63
MTNR1B P49286 2/20 0.63
TP53 P04637 1/20 0.60
TSHR P16473 1/20 0.55
PTGS1 P23219 2/20 0.54
CYP1A2 P05177 1/20 0.53
NQO2 P16083 1/20 0.53
GFER P55789 1/20 0.53
TRPV1 Q8NER1 1/20 0.53
PTGS2 P35354 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23925617 0.89 MAPT (0.87) GOT1MAPTSMN1; SMN2POLBMEN1
SCHEMBL30578783 0.87 MAPT (0.75) GOT1MAPTSMN1; SMN2POLBMEN1
SCHEMBL26430695 0.87 MAPT (0.83) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL23925495 0.86 GOT1 (1.00) GOT1MAPTSMN1; SMN2POLBMEN1
SCHEMBL23925614 0.85 MAPT (0.80) GOT1MAPTSMN1; SMN2POLBMEN1
SCHEMBL23925547 0.82 MAPT (0.78) GOT1MAPTSMN1; SMN2POLBMEN1
SCHEMBL26430691 0.81 MAPT (0.72) GOT1MAPTSMN1; SMN2POLBMEN1
SCHEMBL23925504 0.80 GOT1 (0.78) GOT1MAPTSMN1; SMN2POLBMEN1
SCHEMBL28872563 0.78 MTNR1A (0.76) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL31543697 0.78 MTNR1A (1.00) MAPTSMN1; SMN2POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131376-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC 2023-04-27 US claimed
WO-2021211123-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC (US) 2021-10-21 WO claimed
US-20230131376-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC 2023-04-27 US disclosed
WO-2021211123-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA UNIVERSITY OF NOTRE DAME DU LAC (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230131376-A1 ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA TLR4, TLR5, TLR1 GOT1 871/4885MAPT 1718/4885SMN1; SMN2 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.